AUS
NZ
UK
CA
USA
IND
Highlights:
-
GSK PLC reports positive results from two phase III clinical trials (ANCHOR-1 and ANCHOR-2) for its treatment depemokimab targeting chronic rhinosinusitis with nasal polyps (CRSwNP).
-
Patients treated with depemokimab demonstrated significant reductions in nasal polyp size and nasal blockage compared to those receiving standard care with a placebo.
-
The treatment is administered once every six months, offering a long-lasting solution for patients suffering from CRSwNP.
GSK PLC {LSE:GSK} has announced promising outcomes from two pivotal phase III clinical trials, ANCHOR-1 and ANCHOR-2, evaluating its innovative treatment, depemokimab, for individuals afflicted with chronic rhinosinusitis with nasal polyps (CRSwNP). This condition is characterized by painful inflammation and growths in the nasal passages, resulting in breathing difficulties and other distressing symptoms.
The results from these studies indicate that patients receiving depemokimab experienced a significant reduction in both the size of their nasal polyps and the severity of nasal blockage after 52 weeks of treatment. In contrast, patients receiving standard-of-care treatments alongside a placebo showed less improvement. These findings highlight depemokimab’s potential as an effective therapy for managing the symptoms associated with CRSwNP.
Depemokimab stands out as a long-acting treatment option, requiring administration only once every six months. This dosing schedule is particularly advantageous for patients, as it may enhance adherence to treatment and improve overall quality of life.
Kaivan Khavandi, GSK's head of Research & Development for respiratory and immunology, expressed optimism regarding the study results. He stated, "We're very encouraged by the results from the ANCHOR studies, which demonstrate the potential for depemokimab to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction."
The data generated from these trials, combined with recent phase III findings in severe asthma, are set to be included in regulatory submissions globally. This move positions GSK to advance the treatment of CRSwNP, potentially offering a new and effective option for patients struggling with this challenging condition. The ongoing commitment to research and development in respiratory and immunology by GSK underscores the company’s dedication to addressing unmet medical needs.
